找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz

[復制鏈接]
查看: 21450|回復: 57
樓主
發(fā)表于 2025-3-21 16:57:35 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Clinical Management of Acute Lymphoblastic Leukemia
副標題From Bench to Bedsid
編輯Mark R. Litzow,Elizabeth A. Raetz
視頻videohttp://file.papertrans.cn/229/228051/228051.mp4
概述Presented in a concise, easy-to-read format.Features 100 illustrations, photographs, and tables.Written by experts in the field
圖書封面Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz
描述This book provides a state-of-the-art overview of acute lymphoblastic leukemia (ALL). The first section of the book presents the translational science behind ALL, reviewing molecular pathways and targets in B- and T-cell ALL, as well as techniques and application of minimal residual disease testing. The second section spotlights ALL management strategies for patients across the spectrum, from infants to the elderly. The final section outlines current and new advances in ALL treatment, including new monoclonal antibodies and allogenic and autologous HSCT.?.Written by experts in the field,?.Clinical Management of Acute Lymphoblastic Leukemia: From Bench to Bedsid.e is a valuable resource that will guide patient management, stimulate investigative efforts, and increase understanding of the biologic underpinnings of the disease..
出版日期Book 2022
關鍵詞B-cell ALL; T-cell ALL; minimal residual disease testing; monoclonal antibodies; CAR-T; HSCT
版次1
doihttps://doi.org/10.1007/978-3-030-85147-7
isbn_softcover978-3-030-85149-1
isbn_ebook978-3-030-85147-7
copyrightSpringer Nature Switzerland AG 2022
The information of publication is updating

書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)




書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)學科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡公開度




書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡公開度學科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次




書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次學科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用




書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用學科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋




書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋學科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒有投票權限
沙發(fā)
發(fā)表于 2025-3-21 23:18:52 | 只看該作者
,La régression linéaire multiple,g germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos
板凳
發(fā)表于 2025-3-22 01:46:10 | 只看該作者
Pierre-André Cornillon,Eric Matzner-L?bera second remission followed by allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the advent of targeted therapies such as monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR)-T cells, a better understanding of prognostic genomic markers, refined techniques for d
地板
發(fā)表于 2025-3-22 08:37:56 | 只看該作者
5#
發(fā)表于 2025-3-22 09:52:37 | 只看該作者
6#
發(fā)表于 2025-3-22 16:09:49 | 只看該作者
7#
發(fā)表于 2025-3-22 18:41:14 | 只看該作者
,Theorie ergodique de l’equirepartition,ys and next-generation sequencing technologies, have identified a number of recurrent lesions that can be grouped into several targetable pathways, including Notch, Jak/Stat, MAPK/Ras, PI3K/Akt/mTOR, and cyclin-dependent kinase signaling. Other newer methods to target T-ALL include the use of epigen
8#
發(fā)表于 2025-3-22 21:20:28 | 只看該作者
,Theorie ergodique de l’equirepartition,icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire
9#
發(fā)表于 2025-3-23 04:34:02 | 只看該作者
Molecular Pathways and Targets in B-Cell Progenitor Acute Lymphoblastic Leukemiag germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos
10#
發(fā)表于 2025-3-23 06:39:28 | 只看該作者
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結 SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-18 06:23
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
古浪县| 睢宁县| 双流县| 邓州市| 元阳县| 政和县| 毕节市| 罗源县| 剑川县| 本溪| 游戏| 苍南县| 阿图什市| 怀仁县| 武邑县| 凌云县| 泉州市| 高唐县| 林口县| 文安县| 麟游县| 莲花县| 孙吴县| 化州市| 慈溪市| 务川| 梁山县| 深水埗区| 呼伦贝尔市| 广南县| 滨州市| 革吉县| 沭阳县| 天等县| 通辽市| 临海市| 湖州市| 龙江县| 金堂县| 嘉荫县| 黄骅市|